Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Watson Acquires Generic Revlimid Rights

By R&D Editors | December 7, 2010

NEW YORK (AP) – Watson Pharmaceuticals Inc. said it acquired the U.S. rights to a generic version of Celgene Corp.’s billion-selling cancer drug Revlimid.

Natco Pharma Ltd. is developing a generic version of Revlimid, and the companies reached a deal that would give Watson a share of the profits from U.S. sales of the drug. The companies did not disclose terms of the agreement, but they said Watson will help develop and sell generic versions of Revlimid tablets in strengths of 5, 10, and 25 milligrams. Natco may be the first company to seek marketing approval for generic Revlimid, which would give it six months of marketing exclusivity if its version is approved.

Revlimid is made by Celgene, and U.S. sales of the drug surged to $1.03 billion in the first nine months of the year. U.S. sales of Revlimid have accounted for around 40 percent of Celgene’s revenue in 2010. Shares of Celgene edged up 86 cents to $56.50 in premarket trading.

Revlimid, or lenalidomide, was first approved in December 2005 as a treatment for multiple myeloma, a type of blood cancer. Celgene has lawsuit against Natco that accuses the company of violating patents that protect Revlimid.

Natco is based in Hyderabad, while Watson is based in Morristown, N.J. Celgene’s headquarters are in Summit, N.J.

Date: December 7, 2010
Source: Associated Press

Related Articles Read More >

New nanopore sensor paves the way for fast, accurate, low-cost DNA sequencing
E. coli makes Tylenol from plastic waste
2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE